World Health Organization. Proposed working definition of an older person in Africa for the MDS Project. Available at: http://www.who.int/healthinfo/survey/ageingdefnolder/en/. Published 2002. Accessed September 1, 2018.
Jacobson TA, Maki KC, Orringer CE, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9(suppl 6):S1-122.
Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39:2526-2539.
Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol Sin. 2016;32:631-639.
Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;106:1024-1028.
Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012-1022.
Pharmacology of lipid-lowering medications. In: Wiggins BS, Saseen JJ, eds. The Pharmacist's Guide to Lipid Management. 2nd ed. Lenexa, KS: American College of Clinical Pharmacy; 2014.
Clinical Resource. Characteristics of the Various Statins. Pharmacist's Letter/Prescriber's Letter. 2012;6:280606. Accessed September 1, 2018. http://pharmacistsletter.therapeuticresearch.com/pl/ArticleDD.aspx?nidchk=1&cs=&s=PL&pt=2&segment=4422&dd=280606. Accessed September 1, 2018.
Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
Savarese G, Gotto AM Jr, Paolillo S, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62:2090-2099.
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2107.
Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021-2031.
Ridker PM, Lonn E, Paynter NP, et al. Primary prevention with statin therapy in the elderly: new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials. Circulation. 2017;135:1979-1981.
ClinicalTrials.gov. A clinical trial of STAtin therapy for Reducing Events in the Elderly (STAREE). https://clinicaltrials.gov/ct2/show/NCT02099123. Accessed September 1, 2018.
Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007;115:700-707.
Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997;96:4211-4218.
Heart Protection Study Collaborative Group. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378:2013-2020.
Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998;129:681-689.
Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med. 2001;134:931-940.
Wenger NK, Lewis SJ, Herrington DM, et al. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med. 2007;147:1-9.
Ray KK, Bach RG, Cannon CP, et al. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J. 2006;27:2310-2316.
Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-2934.
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999-3058.
Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
Cooney MT, Selmer R, Lindman A, et al. Cardiovascular risk estimation in older persons: SCORE O.P. Eur J Prev Cardiol. 2016;23:1093-1103.
Kimura T, Inoeu T, Taguchi I, et al. Does high-intensity pitavastatin therapy further improve clinical outcomes? (REAL-CAD). Presented at: the American Heart Association (AHA) Scientific Sessions; November 13, 2017; Anaheim, CA. Abstract LBS.02.
Cohen JD, Aspry KE, Brown AS, et al. Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop. J Clin Lipidol. 2013;7:573-609.
Bansilal S, Castellano JM, Garrido E, et al. Assessing the impact of medication adherence on long-term cardiovascular outcomes. J Am Coll Cardiol. 2016;68:789-801.
Brush JE Jr, Handberg EM, Biga C, et al. 2015 ACC health policy statement on cardiovascular team-based care and the role of advanced practice providers. J Am Coll Cardiol. 2015;65:2118-2136.
Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898.
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.
Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2935-2959.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Panelist

Kausik K. Ray, MD, MPhil, FRCP

Professor of Public Health
Imperial College London
London, United Kingdom

Disclosures

Disclosure: Kausik K. Ray, MD, MPhil, FRCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Cerenis; Ionis; Lilly; Medco; Regeneron Pharmaceuticals, Inc.; Sanofi
Served as a speaker or a member of a speakers bureau for: Alforithm; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; CIPLA; Kowa Company Ltd.; Pfizer Inc.; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Amgen Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi

Dr Ray does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Ray does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Lale Tokgözoğlu, MD, FACC, FESC

Professor of Cardiology
Department of Cardiology
Hacettepe University Faculty of Medicine
Ankara, Turkey

Disclosures

Disclosure: Lale Tokgözoğlu, MD, FACC, FESC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Recordati; Sanofi
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Mylan Laboratories Inc.; Novartis Pharmaceuticals Corporation; Recordati; Sanofi; SERVIER

Dr Tokgözoğlu does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Tokgözoğlu does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Joy P. Marko, MS, APN-C, CCMEP

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Joy P. Marko, MS, APN-C, CCMEP, has disclosed no relevant financial relationships

Katherine L. DeYoung, PhD

DeYoung Medical Writing, LLC
Savannah, GA

Disclosures

Disclosure: Katherine L. DeYoung, PhD, has disclosed no relevant financial relationships

CME Reviewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

CME / CE

Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

Authors: Kausik K. Ray, MD, MPhil, FRCP; Lale Tokgözoğlu, MD, FACC, FESC
CME / CE Released: 9/25/2018
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/25/2019, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for primary care physicians, cardiologists, diabetologists and endocrinologists, nurses, and pharmacists.

The goal of this activity is to improve understanding and clinical expertise regarding the use of statins in older patients.

Upon completion of this activity, participants will:

Have greater knowledge related to
- Tailoring statin therapy in older patients to minimize risk for cardiovascular (CV) recurrence
- Using appropriate team-based care to improve safety of statin therapy and drug-drug interactions in elderly patients

Disclosures

Panelist

Kausik K. Ray, MD, MPhil, FRCP

Professor of Public Health
Imperial College London
London, United Kingdom

Disclosures

Disclosure: Kausik K. Ray, MD, MPhil, FRCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Cerenis; Ionis; Lilly; Medco; Regeneron Pharmaceuticals, Inc.; Sanofi
Served as a speaker or a member of a speakers bureau for: Alforithm; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; CIPLA; Kowa Company Ltd.; Pfizer Inc.; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Amgen Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi

Dr Ray does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Ray does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Lale Tokgözoğlu, MD, FACC, FESC

Professor of Cardiology
Department of Cardiology
Hacettepe University Faculty of Medicine
Ankara, Turkey

Disclosures

Disclosure: Lale Tokgözoğlu, MD, FACC, FESC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Recordati; Sanofi
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Mylan Laboratories Inc.; Novartis Pharmaceuticals Corporation; Recordati; Sanofi; SERVIER

Dr Tokgözoğlu does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Tokgözoğlu does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Joy P. Marko, MS, APN-C, CCMEP

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Joy P. Marko, MS, APN-C, CCMEP, has disclosed no relevant financial relationships

Katherine L. DeYoung, PhD

DeYoung Medical Writing, LLC
Savannah, GA

Disclosures

Disclosure: Katherine L. DeYoung, PhD, has disclosed no relevant financial relationships

CME Reviewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For Nurses

Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-18-206-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Family Medicine

CME / CE

Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

Authors: Kausik K. Ray, MD, MPhil, FRCP; Lale Tokgözoğlu, MD, FACC, FESCFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / CE Released: 9/25/2018

Valid for credit through: 9/25/2019, 11:59 PM EST

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

Download Now

CME / CE Information

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Panelist

Kausik K. Ray, MD, MPhil, FRCP

Lale Tokgözoğlu, MD, FACC, FESC

Editor

Joy P. Marko, MS, APN-C, CCMEP

Katherine L. DeYoung, PhD

CME Reviewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

CME / CE

Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

Target Audience and Goal Statement

Disclosures

Panelist

Kausik K. Ray, MD, MPhil, FRCP

Lale Tokgözoğlu, MD, FACC, FESC

Editor

Joy P. Marko, MS, APN-C, CCMEP

Katherine L. DeYoung, PhD

CME Reviewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?